Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 8/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413275 | 1.00 | ALDH1A1 (0.56) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL2787679 | 0.89 | AR (0.50) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL5066101 | 0.85 | MAOB (0.49) | ALDH1A1KDM4EUSP2MAOBMAOA | |
| SCHEMBL11158058 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL14045403 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL4696820 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL2020304 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL13461882 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL1329661 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL6783952 | 0.82 | KDM4E (0.61) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4537828-A2 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4200301-B1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250034182-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12116380-B2 | Phospholipid compounds and methods of making and using the same | GILEAD SCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4387977-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117858881-A | Phospholipid compounds and methods of making and using the same | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1790652-A1 | Polycyclic guanine phosphodiesterase V inhibitors | Schering Corporation (US) | 2007-05-30 | — | — | EP | disclosed |
| US-6969719-B2 | Polycyclic guanine phosphodiesterase V inhibitors | SCHERING CORPORATION (US) | 2005-11-29 | — | — | US | disclosed |
| US-20030153587-A1 | Polycyclic guanine phosphodiesterase V inhibitors | SCHERING CORPORATION | 2003-08-14 | — | — | US | disclosed |
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |
| EP-1196391-A1 | BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001030745-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001005770-A1 | BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153587-A1 | Polycyclic guanine phosphodiesterase V inhibitors | PDE5A, PDE3A, PDE2A | ALDH1A1 1994/4885KDM4E 2835/4885USP2 2376/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | ALDH1A1 3639/4885KDM4E 3875/4885USP2 4298/4885 |
| US-12116380-B2 | Phospholipid compounds and methods of making and using the same | PHOSPHO1, SGMS1, SGMS2 | ALDH1A1 3704/4885KDM4E 4026/4885USP2 3835/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | ALDH1A1 676/4885KDM4E 3958/4885USP2 2334/4885 |
| US-20250034182-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PHOSPHO1, SGMS1, SGMS2 | ALDH1A1 3704/4885KDM4E 4026/4885USP2 3835/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | ALDH1A1 3639/4885KDM4E 3875/4885USP2 4298/4885 |
| US-11773122-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | ALDH1A1 3639/4885KDM4E 3875/4885USP2 4298/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | ALDH1A1 3639/4885KDM4E 3875/4885USP2 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.